基于MRI靶向穿刺的前列腺癌扩展盆腔淋巴结清扫候选列线图
该研究在497例经MRI靶向穿刺确诊并接受根治性前列腺切除术和扩展盆腔淋巴结清扫的患者中,评估现有淋巴结浸润预测模型的准确性,并开发新列线图。新模型包含PSA、临床分期、mpMRI主病灶最大径、靶向穿刺分级分组及同期系统穿刺临床显著癌,AUC为86%,优于现有模型。使用7%切点可避免57%的ePLND,仅漏诊1.6%的淋巴结浸润患者。
要点
- 现有模型在MRI靶向穿刺人群中对淋巴结浸润预测校准欠佳。
- 新列线图AUC达86%,净获益高于现有模型。
- 7%切点可减少57%的ePLND,漏诊淋巴结浸润仅1.6%。
核心结论
- 现有预测淋巴结浸润的模型在MRI靶向穿刺确诊患者中准确性和临床净获益欠佳。
- 包含mpMRI和MRI靶向穿刺数据的新列线图应在此类人群中用于筛选ePLND候选者。
研究设计与样本
- 回顾性识别5家机构497例经MRI靶向穿刺确诊并接受根治性前列腺切除术和扩展盆腔淋巴结清扫的患者。
- 使用AUC、校准曲线和决策曲线分析评估现有模型,并开发及内部验证新列线图。
主要发现
- 62例(12.5%)存在淋巴结浸润,中位切除淋巴结数为15枚。
- Briganti 2012、Briganti 2017和MSKCC列线图的AUC分别为82%、82%和81%,校准欠佳。
- 新模型AUC为86%,净获益高于基于标准穿刺开发的现有模型。
关键数值与推荐
- 新列线图包含PSA、临床分期、mpMRI主病灶最大径、靶向穿刺分级分组及同期系统穿刺临床显著癌。
- 使用7%切点,可避免244例(57%)ePLND,漏诊淋巴结浸润比例为1.6%。
- 现有列线图在相同切点下漏诊淋巴结浸润比例分别为Briganti 2012 4.6%、Briganti 2017 4.5%、MSKCC 4.2%。
临床怎么用
- 对经MRI靶向穿刺确诊的前列腺癌患者,可采用新列线图筛选ePLND候选者。
- 以7%为切点可减少不必要的ePLND,同时漏诊淋巴结浸润风险较低。
局限性
- 回顾性研究设计。
- 新列线图仅进行内部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies. OBJECTIVE: To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies. DESIGN, SETTING, AND PARTICIPANTS: A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated. RESULTS AND LIMITATIONS: Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC). CONCLUSIONS: Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting. PATIENT SUMMARY: We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI.
引用
- Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2018. PMID: 30342844. doi:10.1016/j.eururo.2018.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。